000007637 001__ 7637
000007637 005__ 20231129124934.0
000007637 0247_ $$2DOI$$a10.6083/m479446z
000007637 037__ $$aETD
000007637 245__ $$aMeasuring and managing phenotypic heterogeneity and plasticity in breast cancer to improve therapeutic control
000007637 260__ $$bOregon Health and Science University
000007637 269__ $$a2017
000007637 336__ $$aDissertation
000007637 502__ $$bPh.D.
000007637 520__ $$aOur ability to therapeutically manage breast tumors has been revolutionized by the use of drugs targeting the activity of the estrogen and HER2 receptors. However, the efficacy of these treatments is restricted to tumors expressing/overexpressing these receptors, leaving the 18% of patients that lack ER and HER2 receptor expression minimal options for therapy. In particular, triple negative (TN) breast cancer patients are limited to a small set of chemotherapeutics for treatment options. Many small molecule kinase inhibitors are currently under clinical investigation for treatment of TN tumors, but despite targeting pathways shown to be commonly upregulated in this subtype, clinical success with these single agent targeted therapies has been poor. In this work we attempt to better understand the resistance mechanisms underlying the innate resistance of TN tumors to targeted kinase inhibitors.
000007637 542__ $$fIn copyright - single owner
000007637 650__ $$aCarcinoma$$016112
000007637 650__ $$aTriple Negative Breast Neoplasms$$040478
000007637 650__ $$aDrug Interactions$$018075
000007637 650__ $$aBreast$$015806
000007637 650__ $$aEpigenomics$$039014
000007637 691__ $$aSchool of Medicine$$041369
000007637 692__ $$aDepartment of Cell, Developmental and Cancer Biology$$041399
000007637 7001_ $$aRisom, Tyler
000007637 8564_ $$9a33d87b6-dc2f-42a3-a902-bea4f2a8cae3$$s12305355$$uhttps://digitalcollections.ohsu.edu/record/7637/files/Risom.Tyler.2017.pdf
000007637 905__ $$a/rest/prod/hh/63/sw/56/hh63sw56s
000007637 909CO $$ooai:digitalcollections.ohsu.edu:7637$$pstudent-work
000007637 980__ $$aTheses and Dissertations